← Leaderboards
Michael J Spinella
Dartmouth College
$5,049,054
Attributed
$5,049,054
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $580.6K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$5,049,054 · 6
By mechanism
R01$3,747,608 · 2
R21$739,365 · 2
K01$407,633 · 1
R03$154,448 · 1
Top collaborators
No co-investigators on record.
Most similar at Dartmouth College
Same institution · by research overlap
- Ethan Dmitrovsky$11,142,103
- Steven D Leach$25,866,740
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsTumorBaseMediatingLinkResistanceCellsNeoplastic CellSignal TransductionMalignant NeoplasmsGene ExpressionResponseChemotherapyDesignGenesMolecularIn VitroChromatinEpigenetic ProcessLifeGeneticHigh RiskGene TargetingInhibitor/Antagonist
Grant awards (21)
DNA Methylation Inhibitor Therapy for Testicular Cancer$440,311
R01 · FY2022 · CA · contact PI
DNA Methylation Inhibitor Therapy for Testicular Cancer$52,440
R01 · FY2022 · CA · contact PI
DNA Methylation Inhibitor Therapy for Testicular Cancer$513,005
R01 · FY2021 · CA · contact PI
DNA Methylation Inhibitor Therapy for Testicular Cancer$449,298
R01 · FY2020 · CA · contact PI
DNA Methylation Inhibitor Therapy for Testicular Cancer$52,308
R01 · FY2020 · CA · contact PI
DNA Methylation Inhibitor Therapy for Testicular Cancer$459,898
R01 · FY2019 · CA · contact PI
A Novel Clinically Relevant Tumor Suppressor in Human Breast Cancer$77,193
R03 · FY2019 · CA · contact PI
DNA Methylation Inhibitor Therapy for Testicular Cancer$503,327
R01 · FY2018 · CA · contact PI
A Novel Clinically Relevant Tumor Suppressor in Human Breast Cancer$77,255
R03 · FY2018 · CA · contact PI
New Cancer Therapeutic Target$211,410
R21 · FY2015 · CA · contact PI
New Cancer Therapeutic Target$176,175
R21 · FY2014 · CA · contact PI
Retinoid Tumor Differentiation Mechanisms$248,648
R01 · FY2008 · CA · contact PI
Epigenetic reprogramming of malignant stem cells of the testes$191,880
R21 · FY2008 · CA · contact PI
Retinoid Tumor Differentiation Mechanisms$248,648
R01 · FY2007 · CA · contact PI
Epigenetic reprogramming of malignant stem cells of the testes$159,900
R21 · FY2007 · CA · contact PI
Retinoid Tumor Differentiation Mechanisms$256,073
R01 · FY2006 · CA · contact PI
Retinoid Tumor Differentiation Mechanisms$262,236
R01 · FY2005 · CA
Retinoid Tumor Differentiation Mechanisms$261,416
R01 · FY2004 · CA
RETINOID INDUCED TUMOR DIFFERENTIATION AND THE CELL CYCL$138,400
K01 · FY2002 · CA
RETINOID INDUCED TUMOR DIFFERENTIATION AND THE CELL CYCL$135,842
K01 · FY2001 · CA
RETINOID INDUCED TUMOR DIFFERENTIATION AND THE CELL CYCL$133,391
K01 · FY2000 · CA